Cargando…

Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia

BACKGROUND: Older patients with acute myeloid leukemia are particularly difficult to treat, as they have a high risk of comorbidities, poor performance status and less tolerability to chemotherapy, as well as a more aggressive disease biology, responsible for the resistance to treatment. There is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Campos, Elisabete do Vale, Pinto, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517609/
https://www.ncbi.nlm.nih.gov/pubmed/31084767
http://dx.doi.org/10.1016/j.htct.2018.09.001